Pfizer and Opko end 2016 downbeat as hGH-CTP fails phase 3

Short resume:

financials
60%
study
50%
biotech
50%
pfizer
50%

Opko’s shares are down more than 17% this morning on the news that its candidate for patients with a rare growth hormone deficiency missed its endpoint in a late-stage test.
Source FierceBiotech
Read More…

More News


Be the first to comment

Leave a Reply

Your email address will not be published.


*